PMID- 30210590
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220408
IS  - 1792-0981 (Print)
IS  - 1792-1015 (Electronic)
IS  - 1792-0981 (Linking)
VI  - 16
IP  - 3
DP  - 2018 Sep
TI  - Effect of montelukast on the expression of CD4(+)CD25(+) regulatory T cells in 
      children with acute bronchial asthma.
PG  - 2381-2386
LID - 10.3892/etm.2018.6485 [doi]
AB  - The aim of this study was to investigate the effect of montelukast on the 
      expression of CD4(+)CD25(+) regulatory T cells in children with acute bronchial 
      asthma. Fifty-six child patients with acute bronchial asthma treated in the 
      Department of Pneumology at the Shangluo Central Hospital were selected and 
      randomly divided into the control group (n=28) and treatment group (n=28). The 
      control group was treated with the conventional therapy of bronchial asthma, 
      while the treatment group received montelukast on the basis of the control group 
      for 7 days. The clinical symptoms, lung function and proportion of CD4(+)CD25(+) 
      regulatory T cells in peripheral T lymphocyte subsets in patients in the two 
      groups were observed. Moreover, the levels of inflammatory factors and 
      immunoglobulin E (IgE) in peripheral blood in both groups were detected. The 
      effective treatment rate in the treatment group was significantly higher than 
      that in the control group (P<0.05), and the forced expiratory volume in 1 
      sec/forced vital capacity (FEV1/FVC), peak expiratory flow (PEF) and 25% peak 
      expiratory flow (PEF25) in the treatment group were significantly higher than 
      those in the control group (P<0.05). The proportions of CD4(+)CD25(+) regulatory 
      T cells in the two groups after drug therapy were significantly increased. The 
      proportion and content per unit volume of peripheral CD4(+)CD25(+) regulatory T 
      cells in the treatment group were obviously higher than those in the control 
      group (P<0.01). After treatment, the levels of interleukin-4 (IL-4), IL-5 and 
      IL-6 in peripheral blood in the two groups were significantly decreased. However, 
      the levels of transferrin-gamma (TFN-gamma) and IL-10 were significantly increased 
      (P<0.01). The IgE level in the treatment group was also significantly higher than 
      that in the control group (P<0.01). In conclusion, montelukast can regulate the T 
      helper 1 (Th1)/Th2 balance, increase the expression of CD4(+)CD25(+) regulatory T 
      cells, and improve the airway inflammation caused by acute bronchial asthma and 
      the clinical symptoms and lung function of patients with acute bronchial asthma.
FAU - Qu, Xiaoting
AU  - Qu X
AD  - Department of Pediatrics, Shangluo Central Hospital, Shangluo, Shaanxi 726000, 
      P.R. China.
FAU - Chen, Yuan
AU  - Chen Y
AD  - Department of Pediatrics, Ankang City Central Hospital of Shaanxi Province, 
      Ankang, Shaanxi 725000, P.R. China.
FAU - Yin, Chaoyang
AU  - Yin C
AD  - Department of Pediatrics, Shangluo Central Hospital, Shangluo, Shaanxi 726000, 
      P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20180719
PL  - Greece
TA  - Exp Ther Med
JT  - Experimental and therapeutic medicine
JID - 101531947
PMC - PMC6122559
OTO - NOTNLM
OT  - CD4+CD25+ regulatory T cells
OT  - bronchial asthma
OT  - inflammatory factors
OT  - montelukast
EDAT- 2018/09/14 06:00
MHDA- 2018/09/14 06:01
PMCR- 2018/07/19
CRDT- 2018/09/14 06:00
PHST- 2017/12/28 00:00 [received]
PHST- 2018/07/06 00:00 [accepted]
PHST- 2018/09/14 06:00 [entrez]
PHST- 2018/09/14 06:00 [pubmed]
PHST- 2018/09/14 06:01 [medline]
PHST- 2018/07/19 00:00 [pmc-release]
AID - ETM-0-0-6485 [pii]
AID - 10.3892/etm.2018.6485 [doi]
PST - ppublish
SO  - Exp Ther Med. 2018 Sep;16(3):2381-2386. doi: 10.3892/etm.2018.6485. Epub 2018 Jul 
      19.